[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346424-105":59,"doc-detail-346424-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pan-cancer-analysis-of-trpv1-a-novel-immune-infiltration-related-biomarker-for-tumor-prognosis-and-immunotherapy-response-prediction","Pan-cancer analysis of TRPV1 - a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction","","TRPV1-related mechanisms in cancer remain insufficiently defined, motivating a pan-cancer assessment of Transient receptor potential vanilloid 1 (TRPV1) across expression, prognostic value, single-cell characteristics, immune infiltration, and immune checkpoint (ICI) associations. TRPV1 was markedly upregulated in 13 cancers and linked to poorer outcomes. Expression correlated with immune cell infiltration and ICI patterns. In vitro functional assays, including cellular function and western blot analyses, indicate TRPV1 may support migration in head and neck and lung cancers via PI3K/AKT inhibition and coordinated enhancement of immune infiltration and autophagy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-cancer-analysis-of-trpv1-a-novel-immune-infiltration-related-biomarker-for-tumor-prognosis-and-immunotherapy-response-prediction/346424/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-of-trpv1-a-novel-immune-infiltration-related-biomarker-for-tumor-prognosis-and-immunotherapy-response-prediction/346424.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why study TRPV1 across pan-cancer rather than in one cancer type?","Question",{"text":113,"@type":114},"TRPV1 has been investigated in cancer, but its role in regulating the tumor microenvironment and predicting outcomes across cancer types is unclear. A pan-cancer approach evaluates its expression patterns and associations more comprehensively.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What relationship was found between TRPV1 expression and patient prognosis?",{"text":118,"@type":114},"TRPV1 was significantly upregulated in 13 cancers and closely correlated with poor prognosis, indicating prognostic relevance.",{"name":120,"@type":111,"acceptedAnswer":121},"How might TRPV1 influence the tumor microenvironment and immunotherapy response?",{"text":122,"@type":114},"TRPV1 expression correlated with immune cell infiltration and immune checkpoint (ICI) patterns. Functional experiments suggest TRPV1 may modulate the tumor microenvironment by affecting immune-related physiological activities, including PI3K/AKT signaling inhibition and changes involving immune infiltration and autophagy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},346424,1790195309,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Wang et al. BMC Cancer (2026) 26:216 [https://doi.org/10.1186/s12885-026-15576-4](https://doi.org/10.1186/s12885-026-15576-4)  \nBMC Cancer  \nRESEARCH Open Access  \nPan-cancer analysis of TRPV1: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction  \nFeixiang Wang1†, Boyun Deng2†, Maohua Qin3, Zijin Cheng4, Jian Zhang3* and Guofeng Xie3*  \nAbstract  \nThere were several studies on Transient receptor potential vanilloid 1 (TRPV1), the research on TRPV1 in cancer remains unclear. The expression, prognostic, single-cell value, immune cell infiltration, and immune check-point (ICI) of TRPV1 in pan-cancer were assessed. Functional assays were performed to evaluate the effect of TRPV1 in vitro. TRPV1 was significantly upregulated in 13 cancers, and was closely correlated with poor prognosis. Moreover, the expression of TRPV1 was significantly correlated with the infiltration of immune cells and ICI. Cellular function and western blot experiments revealed that TRPV1 may be required for cancer cell migration in head and neck cancer and lung cancer by inhibition of PI3K/AKT and promotion of immune cell infiltration and autophage. Our study suggests that TRPV1 may be able to regulate the tumor microenvironment by regulating immune-related physiological activities and thereby regulating the occurrence and progression of cancers. Thus, TRPV1 could be used to develop new-targeted drugs for cancers.  \nKeywords TRPV1, Prognosis, Single-cell, Tumor microenvironment, Pan-cancer  \n†Feixiang Wang and Boyun Deng contributed equally to this work.  \n*Correspondence:  \nJian Zhang [zhangjian@gzhmu.edu.cn](zhangjian@gzhmu.edu.cn)[ ](zhangjian@gzhmu.edu.cn)Guofeng Xie [xieguofeng@gzhmu.edu.cn](xieguofeng@gzhmu.edu.cn)  \n1Department of Thoracic Surgery, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China  \n2Department of Thoracic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China  \n3Department of Radiation Oncology, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China  \n4School of Life Science Fudan University, Shanghai, China  \nIntroduction  \nCancer is the leading cause of death worldwide and a major impediment to extending life expectancy [1]. An estimated 19.3 million new cancer diagnoses and about 10.0 million cancer deaths worldwide occurred in 2020 [2], with few effective cancer therapies available thus far. Cancer immunotherapy, particularly immune checkpoint inhibitors, has emerged as one of the most promising therapeutic methods in recent years [3–5]. The tumor microenvironment (TME), on the other hand, has been widely investigated in the cancer literature, with a particular emphasis on its involvement in cancer occurrence and progression [6–8], as well as its potential as a cancer therapeutic target [9, 10].  \nTumor cells and their surrounding immune cells, tumor-related fibroblasts, vascular endothelial cells,  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommo","cbCaingNnlzUumDB","https://ap.wps.com/l/cbCaingNnlzUumDB","pdf",11796756,12,"English","# Abstract\n# Introduction\n## Cancer burden and immunotherapy context\n## Tumor microenvironment and immunotherapeutic biomarkers\n## TRPV1 background and rationale","[{\"question\":\"Why study TRPV1 across pan-cancer rather than in one cancer type?\",\"answer\":\"TRPV1 has been investigated in cancer, but its role in regulating the tumor microenvironment and predicting outcomes across cancer types is unclear. A pan-cancer approach evaluates its expression patterns and associations more comprehensively.\"},{\"question\":\"What relationship was found between TRPV1 expression and patient prognosis?\",\"answer\":\"TRPV1 was significantly upregulated in 13 cancers and closely correlated with poor prognosis, indicating prognostic relevance.\"},{\"question\":\"How might TRPV1 influence the tumor microenvironment and immunotherapy response?\",\"answer\":\"TRPV1 expression correlated with immune cell infiltration and immune checkpoint (ICI) patterns. Functional experiments suggest TRPV1 may modulate the tumor microenvironment by affecting immune-related physiological activities, including PI3K/AKT signaling inhibition and changes involving immune infiltration and autophagy.\"}]","Pan-cancer analysis of TRPV1 - a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction | PDF",1790061407,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9727cb16aebb78e4467a2c05bedd085c.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/daeba5fc6bb6432a88e512eef64e8f58.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46b4c9977e21520ab1440e244f07b245.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0161a923e86ef9e88c403f7f74502402.webp",980,1306]